← Eichor
Study identifier: NCT05862259 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies

Condition: Malignant Tumor · Immunotherapy · Artificial Intelligence  ·  Sponsor: Xinqiao Hospital of Chongqing

PhaseN/A
Planned participants120
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

In this study, we collected the data of immunohistochemistry, gene detection, image, OS, PFS, Orr, and so on. Secondly, the database of immunotherapy for malignant tumor was established, and the predictive model was constructed to verify and establish the rationality and validity of the biomarkers and predictive system of immunotherapy

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

the second affiliated hospital of Army medical universityChongqing, Chongqing Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05862259